Table 1.
Reactivity of autoimmune patient sera with components of the human exosome
| Exosome component | IIM [no. (%)] | Myositis/scleroderma overlap syndrome [no. (%)] | Scleroderma [no. (%)] |
| Total number analyzed | 48 | 10 | 11 |
| PM/Scl-100a | 45 (94) | 10 (100) | 11 (100) |
| PM/Scl-75a | 26 (54) | 9 (90) | 7 (64) |
| hRrp4pb | 25 (52) | 6 (60) | 7 (64) |
| hRrp40pb | 3 (6) | 1 (10) | 0 |
| hRrp41pb | 5 (10) | 0 | 0 |
| hRrp42pb | 11 (23) | 2 (20) | 4 (36) |
| hRrp46pb | 6 (13) | 0 | 0 |
| hCsl4pb | 7 (15) | 0 | 0 |
| Total reactivity with novel components | 30 (63) | 6 (60) | 8 (73) |
aAnti-PM/Scl-100 and anti-PM/Scl-75 reactivity of IIM sera was previously analyzed [28]. bNovel human exosome components analyzed in this study. IIM = idiopathic inflammatory myopathies; PM/Scl = polymyositis/scleroderma.